# Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

> **NCT00567996** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1002 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Indacaterol 150 μg
- **DRUG:** Salmeterol 50 μg
- **DRUG:** Placebo to Indacaterol
- **DRUG:** Placebo to Salmeterol

## Key facts

- **NCT ID:** NCT00567996
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 1002 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00567996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00567996, "Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00567996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*